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Abacavir belongs among nucleoside reverse transciptase inhibitors (NRTIs) 
representing a basic component of combined antiretroviral therapy used in treatment  
of HIV-positive patients [1]. Etravirine and rilpivirine are newer non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) combined in cART together with NRTI. 
ATP-dependent transporters, so called ABC transporters, are able to affect 
pharmacokinetic properties of drugs, thus they are important site of drug-drug interact ions 
affecting absorption, distribution and excretion level. P-glycoprotein (Pgp, ABCB1) and 
BCRP (ABCG2) belong among the most clinically important ABC transporters able to 
cause drug-drug interactions. 
The aim of this thesis was to introduce and optimize the method for evaluation  
of drug absorption using monolayers of Caco-2 human intestine cell lines, whose integr ity 
was verified by evaluating TEER (transepithelial electrical resistance). This model was 
also used for abacavir transport studies. Significant asymmetry was observed in transport 
of abacavir across Caco-2 monolayer in basolateral-apical direction in contrast  
to apical-basolateral direction. The asymmetry was completely reduced by adding 
elacridar (dual inhibitor Pgp and BCRP). The follow up transport study with rilpivir ine 
and etravirine revealed that both antiretrovirotics affect abacavir permeability across  
the cell monolayer, most probably due to inhibition of ABC eflux tranporters  
(Pgp and BCRP). Based on our results, we suggest that both, etravirine and rilpivir ine, 
are able to cause drug-drug interactions that might affect abacavir absorption and lead to 
its increased bioavailability. Such interaction might call for adjustments in abacavir 
dosage when co-administered with one of those NNRTIs in clinical settings. 
 
